Person Closely Associated Dealing
Oxford, UK - 03 July 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that Pippa Radcliffe, a person closely associated with Kyriacos Mitrophanous, Chief Innovation Officer of the Company, exercised 2,000 options at exercise price of £2.747 and disposed 1,841 shares at £3.0008 per share on 2 July 2024.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of the Person Closely Associated ("PCA") | |||||
| a) | Name | Pippa Radcliffe | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | This notification concerns Pippa Radcliffe in her capacity as a person closely associated with a person discharging managerial responsibilities. The person discharging managerial responsibilities is Kyriacos Mitrophanous, Chief Innovation Officer of the Company. The association arises by virtue of Pippa Radcliffe being the spouse of Kyriacos Mitrophanous.
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Exercise of Options at exercise price of £2.747 | ||||
| c) | Currency | GBP - British pound | ||||
| d) | Price(s) and volumes(s)
|
| ||||
| e) | Aggregated information - Aggregate volume - Price - Aggregated total
|
2,000
£2.747 £5,494 | ||||
| f) | Date of the transaction | 2024-07-02 | ||||
| g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
| a) | Name | Pippa Radcliffe | ||||
| 2. | Reason for the notification | |||||
| a) | Position/status | This notification concerns Pippa Radcliffe in her capacity as a person closely associated with a person discharging managerial responsibilities. The person discharging managerial responsibilities is Kyriacos Mitrophanous, Chief Innovation Officer of the Company. The association arises by virtue of Pippa Radcliffe being the spouse of Kyriacos Mitrophanous.
| ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Name | Oxford BioMedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
| b) | Nature of the transaction | Disposal | ||||
| c) | Currency | GBP - British pound | ||||
| d) | Price(s) and volumes(s) |
| ||||
| e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
1,841
£3.0008
£5,524.47 | ||||
| f) | Date of the transaction | 2024-07-02 | ||||
| g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
| For further information, please contact: | |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
ABOUT OXFORD BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
